ArticleBMC gastroenterology2022

MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.

Li Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.